癌症单株抗体市场规模、份额和成长分析（按类型、应用、最终用户和地区）：产业预测（2024-2031）

2022年全球癌症单株抗体市场规模估值为739亿美元，从2023年的875亿美元扩大到2031年的3379.2亿美元，在预测期内（2024-2031）预计复合年增长率为18.40% 。

单株抗体 (mAb) 疗法越来越被认为是癌症治疗的重要组成部分，是化疗、放射线治疗和手术等传统治疗方法的补充。在过去的二十年中，单株抗体已被确立为治疗固体癌和骨髓恶性肿瘤的高效治疗方法，刺激了癌症发病率的上升和新药认证的强劲管道。目前和即将核准的单株抗体疗法与传统化疗相比具有副作用相对较少的治疗优势，并有可能使全世界数百万人受益。医疗保健提供者对负担得起的生物相似药单株抗体的接受程度不断提高，预计将在预测期内进一步促进市场成长。然而，COVID-19 疫情对癌症筛检率产生了负面影响，与先前相比，2020 年 4 月乳癌筛检率大幅下降了 87%。这种下降导致了治疗的严重延误，引发了人们对及时获得所需抗癌药物、疾病復发和治疗延迟的担忧。由于癌症仍然是一种以不受控制的细胞增殖为特征的主要慢性疾病，癌症发生率的上升可能会继续推动对单株抗体疗法的需求并支持市场扩张。总体而言，在创新癌症治疗的需求和疫情后医疗保健取得的发展的推动下，癌症市场的单株抗体领域有望成长。

目录

介绍

• 分析目的
• 定义
• 市场范围

分析方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

癌症单株抗体市场：依类型

• 市场概况
• 人性化
• 人类
• 嵌合体
• 老鼠

癌症单株抗体市场：依应用分类

• 市场概况
• 血癌
• 乳癌
• 肺癌
• 恶性黑色素瘤
• 大肠直肠癌
• 肝癌
• 其他的

癌症单株抗体市场：依最终用户分类

• 市场概况
• 医院
• 研究所
• 其他的

癌症单株抗体市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• 艾伯维公司（美国）
• 安进公司（美国）
• 默克公司（美国）
• 百时美施贵宝公司（美国）
• 吉利德科学公司（美国）
• 武田製药公司（日本）
• 阿斯特捷利康公司（英国）
• 礼来公司（美国）
• 再生元製药公司（美国）
• 百济神州有限公司 (中国)
• 百健公司（美国）
• Recordati Industria Chimica e Farmaceutica SpA（义大利）
• 辉瑞（美国）
• Spectrum Pharmaceuticals, Inc.（美国）
• Iovance Biotherapeutics, Inc.（美国）
• Exelixis, Inc.（美国）
• OncoOne（美国）
• CureVac AG（德国）
• Cellerant Therapeutics, Inc.（美国）
• Celltrion, Inc.（韩国）
• Faron 製药股份有限公司（芬兰）

Global Cancer Monoclonal Antibodies Market size was valued at USD 73.9 billion in 2022 and is poised to grow from USD 87.5 billion in 2023 to USD 337.92 billion by 2031, growing at a CAGR of 18.40% during the forecast period (2024-2031).

Monoclonal antibody (mAb) therapies are increasingly recognized as crucial components in the cancer treatment landscape, complementing traditional modalities such as chemotherapy, radiation, and surgery. Over the past two decades, mAbs have established themselves as highly effective treatments for both solid tumors and hematologic malignancies, spurred by rising cancer incidence rates and a robust pipeline of new drug approvals. Current and forthcoming mAb therapies hold the potential to benefit millions globally, offering a therapeutic advantage due to their relatively lower side effects compared to conventional chemotherapy. The growing acceptance of affordable biosimilar monoclonal antibodies by healthcare providers is expected to further enhance market growth in the forecast period. However, the COVID-19 pandemic has negatively impacted cancer screening rates, with a dramatic 87% drop observed in breast cancer screenings in April 2020 compared to previous years. This decline resulted in significant treatment delays, raising concerns about timely access to necessary cancer medications, disease recurrence, and the postponement of therapies. As cancer remains a major chronic disease characterized by unchecked cell proliferation, the escalating incidence of cancer cases will likely continue to drive demand for mAb therapies and bolster market expansion in the coming years. Overall, the mAb segment of the oncology market stands poised for growth, fueled by both the need for innovative cancer treatments and the evolution of healthcare access in a post-pandemic landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Monoclonal Antibodies Market Segmental Analysis

Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is significantly driven by the alarming rise in cancer prevalence worldwide, which underscores the urgent need for innovative and effective treatment options. Monoclonal antibodies are favored over traditional therapies due to their ability to selectively target malignant cells, thereby improving treatment efficacy and minimizing adverse effects. As patient demand for advanced therapeutic solutions escalates, the market is further bolstered by increased investments in research and development aimed at discovering novel monoclonal antibody-based therapies. Furthermore, heightened awareness surrounding cancer leads to earlier detection and treatment initiation, propelling growth and development within this vital sector of oncology.

Restraints in the Global Cancer Monoclonal Antibodies Market

A significant market restraint for the global cancer monoclonal antibodies market is the prohibitively high cost associated with monoclonal antibody therapies. The advanced manufacturing processes and extensive research and development required for these therapies contribute to their steep pricing. This financial burden limits patient access, particularly among low-income communities and in countries with strained healthcare budgets. As a result, the expensive nature of these treatments may render them unaffordable for many, leading to increased out-of-pocket expenses and further hindering market growth and accessibility. This economic barrier could ultimately restrict the adoption of these potentially life-saving therapies across diverse populations.

Market Trends of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is witnessing a significant trend towards the integration of combination therapies, reflecting an evolving landscape in oncology treatment. By leveraging monoclonal antibodies in conjunction with immunotherapies, targeted therapies, and chemotherapy, healthcare providers aim to combat cancer on multiple fronts, enhancing treatment efficacy while minimizing resistance. The synergistic effects observed, particularly with immune checkpoint inhibitors paired with monoclonal antibodies, underscore the potential for improved patient outcomes through deeper immune responses against tumors. This trend not only highlights the complexity of cancer but also emphasizes the shift towards personalized medicine, offering tailored and potent treatment options for diverse patient profiles.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Cancer Monoclonal Antibodies Market by Type

• Market Overview
• Humanized
• Human
• Chimeric
• Murine

Cancer Monoclonal Antibodies Market by Application

• Market Overview
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

Cancer Monoclonal Antibodies Market by End-user

• Market Overview
• Hospitals
• Research Institutes
• Others

Cancer Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoOne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faron Pharmaceuticals Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments